查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2066113

抗減肥藥市場：2026-2032年全球市場預測（依藥物類別、作用機制、給藥途徑、適應症、最終用戶及通路分類）

Anti-Obesity Therapeutics Market by Drug Class, Mechanism of Action, Route Of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗減肥藥市場將成長至 212.1 億美元，複合年成長率為 8.87%。

主要市場統計數據
基準年 2025 116.9億美元
預計年份：2026年 126.7億美元
預測年份 2032 212.1億美元
複合年成長率 (%) 8.87%

抗減肥藥市場正從生活方式輔助支持轉向實證慢性病管理。世界衛生組織（世衛組織）的數據顯示，自1990年以來，成人肥胖率加倍多，到2022年，全球肥胖人口超過10億，其中8.9億為成人，1.59億為兒童和青少年。

關於GLP-1受體促效劑、GIP/GLP-1雙重促效劑、心臟代謝結局以及保險公司將肥胖症重新評估為一種長期疾病的證據，正在推動商業性和臨床發展。 STEP和SURMOUNT試驗的臨床數據表明，在特定研究人群中，使用2.4 mgSemaglutide可使體重減輕近15%，使用替澤帕肽可使體重減輕超過20%，這些數據重新定義了人們對肥胖症藥物治療的預期，並進一步提高了人們對持續治療效果、耐受性和患者治療依從性的關注。

肥胖症治療前景的變革性變化

治療格局正在發生巨大變化，從短期減重產品轉向針對肥胖相關併發症的慢性代謝療法。基於腸促胰素的先進減肥藥已獲得監管部門批准，並在臨床實踐中得到更廣泛的應用，這正在加速醫生採納、患者需求以及注射類減肥藥整體生產規模的擴大。

人工智慧（AI）的累積影響

人工智慧（AI）對肥胖症治療的各個階段都產生了越來越顯著的影響，從藥物發現和臨床開發到商業化和患者支持。人工智慧驅動的分子建模、表現型分析、臨床試驗受試者招募分析和安全訊號檢測正在幫助加速腸促胰素、口服胜肽、Amylin類似物、腸激素聯合治療和下一代代謝療法等藥物研發管線的決策。

對關鍵區域的洞察

北美地區由於肥胖症盛行率高、擁有強大的專科醫生網路、成熟的保險報銷體係以及GLP-1減肥藥的快速普及，仍然是商業性程度最高的地區。在歐洲，由於統一的監管路徑、國家衛生技術評估以及肥胖症作為一種慢性疾病的日益普及，市場正在擴張，儘管各國的醫療服務可及性存在差異，且預算問題仍然十分突出。亞太地區正在崛起為一個重要的戰略區域，中國、印度、日本、韓國和澳洲都面臨著代謝性疾病負擔日益加重、都市區生活方式不斷變化以及對私人醫療保健需求不斷成長的挑戰。

關鍵小組洞察

七國集團（G7）憑藉其先進的監管體系、專業的處方能力、完善的藥品報銷管道以及較高的心血管代謝疾病診斷率，構成了抗減肥藥最強大的臨床和商業性基礎。歐盟在打入市場策略中發揮著至關重要的作用，其定價、報銷和藥物技術評估決策影響著藥物在成員國間的推廣，並塑造著長期肥胖藥物療法的證據要求，包括永續性、安全性、降低合併症發生率和預算影響管理。

主要國家的概況

美國是全球抗減肥藥需求中心，這得益於監管部門的批准、醫生廣泛的處方意識、雇主提供的醫療保險覆蓋範圍以及高肥胖率。根據美國疾病管制與預防中心（CDC）的數據，2021年8月至2023年8月期間，美國成年人的肥胖率高達40.3%。在加拿大，關於公共和私人保險報銷以及系統性醫療技術評估的討論正在進行中。同時，墨西哥和巴西在肥胖、第二型糖尿病、心血管疾病風險和飲食結構改變方面面臨巨大的公共衛生需求。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的臨床證據，這些證據不僅限於減重，還應涵蓋心血管結局、糖尿病預防、阻塞型睡眠呼吸中止症症、代謝功能障礙相關的脂肪肝、腎功能指標、運動功能以及生活品質的改善。保險公司越來越要求提供持續療效的證據、對藥物依從性的支持、合適的患者選擇以及減少肥胖相關併發症的證據，以此來證明擴大承保範圍的合理性。

調查方法

本執行摘要基於來自世界衛生組織 (WHO)、美國疾病管制與預防中心 (CDC)、美國食品藥物管理局管理局 (FDA)、歐洲藥品管理局 (EMA)、各國衛生部門以及同行評審的臨床試驗資訊來源等來源的經檢驗的公共衛生、監管和臨床證據。關鍵證據包括肥胖盛行率趨勢、法規核准、臨床療效數據、安全性結果、心臟代謝結局以及醫療保健系統可近性的考量。

結論

抗減肥藥正處於一個關鍵的轉折點，這主要得益於臨床療效、心臟代謝結果數據以及患者需求的全面推動。該領域的定義不再僅限於減重，而是與降低心血管風險、控制糖尿病、治療肝臟和睡眠相關合併症、提高醫療保健系統效率以及管理長期慢性疾病等目標日益緊密地聯繫在一起。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：抗減肥藥市場：依藥物類別分類

  • 處方藥
    • GLP-1受體促效劑
      • Semaglutide
      • Liraglutide
      • 蒂爾澤帕蒂德
    • 聯合治療
      • 托吡拉芬特明
      • 安非他酮納曲酮
    • 脂肪酶抑制劑
    • 交感神經興奮劑
  • 非處方藥

第8章：抗減肥藥市場：按作用機制分析

  • 中樞作用藥物
    • 食慾抑制劑
    • 神經傳導調變器
  • 周邊促效劑
    • 脂質吸收抑制劑
    • 代謝加速器
  • 荷爾蒙治療方法

第9章：抗減肥藥市場：依給藥途徑分類

  • 口服
    • 膠囊
    • 藥片
  • 注射藥物
    • 肌肉內部
    • 皮下
  • 經皮給藥

第10章：抗減肥藥市場：依適應症分類

  • 肥胖
  • 超重並伴隨其他疾病
    • 2型糖尿病
    • 心血管疾病
    • 高血壓
    • 血脂異常症
  • 遺傳性肥胖症
  • 下視丘性肥胖

第11章：抗減肥藥市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 減重中心
  • 居家照護環境
  • 門診手術中心

第12章：抗減肥藥市場：依通路分類

  • 離線
  • 線上

第13章：抗減肥藥市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：抗減肥藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：抗減肥藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Aardvark Therapeutics
  • Altimmune, Inc.
  • Amgen Inc.
  • Antag Therapeutics ApS
  • Ascletis Pharma Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • Hanmi Pharm. Co., Ltd.
  • Innovent Biologics, Inc.
  • Kailera Therapeutics
  • Metsera, Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sciwind Biosciences
  • Structure Therapeutics Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viking Therapeutics, Inc.
  • Zealand Pharma A/S
  • Zydus Lifesciences Limited
Product Code: MRR-EC2E133E33E6

The Anti-Obesity Therapeutics Market is projected to grow by USD 21.21 billion at a CAGR of 8.87% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.69 billion
Estimated Year [2026] USD 12.67 billion
Forecast Year [2032] USD 21.21 billion
CAGR (%) 8.87%

The anti-obesity therapeutics market is moving from adjunct lifestyle support to evidence-based chronic disease management. World Health Organization data show that adult obesity has more than doubled since 1990, with more than 1 billion people living with obesity globally in 2022, including 890 million adults and 159 million children and adolescents.

Commercial and clinical momentum is being driven by GLP-1 receptor agonists, dual GIP/GLP-1 agonists, cardiometabolic outcome evidence, and payer reassessment of obesity as a long-term medical condition. Clinical data from STEP and SURMOUNT trials, including weight reductions approaching 15% with semaglutide 2.4 mg and more than 20% with tirzepatide in selected trial populations, have reset expectations for obesity pharmacotherapy and intensified focus on durable outcomes, tolerability, and patient persistence.

Transformative Shifts in the Obesity Treatment Landscape

The landscape is being transformed by the shift from short-duration weight-loss products to chronic metabolic therapies that address obesity-related complications. Regulatory approvals of advanced incretin-based obesity medicines, along with expanding real-world use, have accelerated physician adoption, patient demand, and manufacturing scale-up across injectable obesity drugs.

A second major shift is the convergence of obesity care with cardiovascular, renal, hepatic, sleep, and diabetes management. The SELECT trial reported a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease, strengthening the value proposition for payers and health systems. This evidence is pushing anti-obesity therapeutics beyond cosmetic weight reduction toward measurable cardiometabolic risk reduction.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing anti-obesity therapeutics across discovery, clinical development, commercialization, and patient support. AI-enabled molecular modeling, phenotyping, trial recruitment analytics, and safety signal detection are helping accelerate pipeline decisions for incretin-based drugs, oral peptides, amylin analogs, gut hormone combinations, and next-generation metabolic therapies.

In clinical practice, AI can support obesity risk stratification, adherence prediction, dose-titration workflows, and integrated monitoring of cardiometabolic markers such as glycemic control, blood pressure, lipid levels, and liver health indicators. The strongest near-term impact is expected in identifying patients likely to benefit, improving persistence, and supporting evidence generation from real-world data while maintaining privacy protection, bias control, explainability, and regulatory-grade validation.

Key Regional Insights

North America remains the most commercially advanced region due to high obesity prevalence, strong specialist networks, mature reimbursement infrastructure, and rapid uptake of GLP-1-based obesity pharmacotherapy. Europe is expanding through centralized regulatory pathways, national health technology assessments, and increasing recognition of obesity as a chronic disease, although access varies by country and budget impact concerns remain significant. Asia-Pacific is emerging as a major strategic region as China, India, Japan, South Korea, and Australia confront rising metabolic disease burdens, urban lifestyle changes, and expanding private healthcare demand.

Latin America shows meaningful medical need, led by Mexico and Brazil, where obesity and type 2 diabetes are major public health priorities and nutrition-related chronic disease policies are increasingly prominent. The Middle East, especially GCC markets, is adopting premium metabolic therapies amid high diabetes prevalence, advanced private care infrastructure, and growing interest in preventive cardiometabolic medicine. Africa remains earlier-stage for anti-obesity therapeutics, with access constrained by affordability, diagnostic gaps, medicine availability, and health system capacity, even as urbanization and noncommunicable disease burdens increase across the region.

Key Group Insights

The G7 represents the strongest clinical and commercial base for anti-obesity therapeutics because of advanced regulatory systems, specialist prescribing capacity, established pharmaceutical reimbursement channels, and high levels of cardiometabolic disease diagnosis. The European Union is pivotal for market access strategy, as pricing, reimbursement, and health technology assessment decisions influence uptake across member states and shape evidence requirements for long-term obesity pharmacotherapy, including durability, safety, comorbidity reduction, and budget impact management.

BRICS markets are strategically important because they combine large populations, rising obesity prevalence, expanding middle-class demand, and growing local manufacturing capabilities. ASEAN offers a developing opportunity through urbanization, diabetes prevention priorities, and increasing investment in private healthcare systems, while the GCC is characterized by high cardiometabolic disease burden, premium care adoption, and strong demand for advanced metabolic interventions. NATO is not a healthcare market bloc, but its member economies include many high-income systems where supply security, medicine resilience, regulatory coordination, and advanced clinical infrastructure influence therapeutic availability and continuity of care.

Key Country Insights

The United States is the global demand center for anti-obesity therapeutics, supported by regulatory approvals, broad prescriber awareness, employer health benefits, and high obesity prevalence; CDC data reported U.S. adult obesity prevalence at 40.3% during August 2021 to August 2023. Canada is progressing through public and private reimbursement debates and structured health technology evaluation, while Mexico and Brazil face substantial public health need linked to obesity, type 2 diabetes, cardiovascular disease risk, and changing dietary patterns.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are balancing strong clinical demand against budget impact, with Germany and the United Kingdom serving as influential evidence and access markets because of structured assessment processes and specialist clinical networks. France, Italy, and Spain continue to emphasize reimbursement discipline, prescriber guidance, and long-term value demonstration, while Russia remains shaped by local regulatory requirements, affordability considerations, and supply-chain factors.

China and India represent large-scale growth opportunities due to rising obesity rates, expanding diabetes burdens, and increasing investment in metabolic care, although affordability and broad access remain important constraints. Japan and South Korea emphasize metabolic risk management, aging-population health priorities, and clinical evidence standards, supporting measured adoption of obesity pharmacotherapy. Australia combines high disease awareness with structured reimbursement evaluation and established obesity, diabetes, and cardiovascular care pathways, making evidence quality and cost-effectiveness central to access decisions.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical evidence beyond weight loss, including cardiovascular outcomes, diabetes prevention, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, renal markers, mobility, and quality-of-life improvements. Payers increasingly require proof of durable benefit, adherence support, appropriate patient selection, and reduced obesity-related complications to justify broader coverage.

Companies should also invest in scalable manufacturing, cold-chain resilience, oral and longer-acting formulations, pharmacovigilance systems, equitable pricing models, and real-world evidence programs. Partnerships with primary care networks, endocrinologists, cardiologists, hepatologists, sleep specialists, digital health providers, and employers can improve diagnosis, treatment persistence, and outcomes in the anti-obesity therapeutics market. Responsible communication, patient education, and continuity-of-care models will be critical to maintaining trust as demand expands.

Research Methodology

This executive summary is based on verified public health, regulatory, and clinical evidence from sources such as the World Health Organization, U.S. Centers for Disease Control and Prevention, U.S. Food and Drug Administration, European Medicines Agency, national health authorities, and peer-reviewed clinical trial publications. Key evidence includes obesity prevalence trends, regulatory approvals, clinical efficacy data, safety findings, cardiometabolic outcomes, and health system access considerations.

The methodology combines secondary research, cross-validation of clinical and regulatory milestones, assessment of regional healthcare structures, and analysis of market access dynamics. Insights are synthesized to reflect current conditions in anti-obesity therapeutics, including GLP-1 receptor agonists, dual incretin agonists, emerging oral therapies, amylin-based approaches, and next-generation metabolic drug pipelines, while avoiding market sizing, market share, and forecasting claims.

Conclusion

Anti-obesity therapeutics are entering a pivotal phase as clinical efficacy, cardiometabolic outcome data, and patient demand converge. The sector is no longer defined only by weight reduction; it is increasingly linked to cardiovascular risk reduction, diabetes management, liver and sleep-related comorbidity care, health system efficiency, and long-term chronic disease management.

Sustained leadership will depend on evidence quality, manufacturing reliability, affordability, equitable access, safety monitoring, and the ability to integrate pharmacotherapy with digital care, nutrition, physical activity, and behavioral support. Organizations that demonstrate durable health outcomes, responsible commercialization, and patient-centered access are best positioned to shape the next decade of obesity treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Anti-Obesity Therapeutics Market, by Drug Class

  • 7.1. Prescription Drugs
    • 7.1.1. GLP 1 Receptor Agonists
      • 7.1.1.1. Semaglutide
      • 7.1.1.2. Liraglutide
      • 7.1.1.3. Tirzepatide
    • 7.1.2. Combination Therapies
      • 7.1.2.1. Phentermine Topiramate
      • 7.1.2.2. Bupropion Naltrexone
    • 7.1.3. Lipase Inhibitors
    • 7.1.4. Sympathomimetic Agents
  • 7.2. Over the Counter Drugs

8. Anti-Obesity Therapeutics Market, by Mechanism of Action

  • 8.1. Centrally Acting Drugs
    • 8.1.1. Appetite Suppressants
    • 8.1.2. Neurotransmitter Modulators
  • 8.2. Peripherally Acting Drugs
    • 8.2.1. Fat Absorption Blockers
    • 8.2.2. Metabolic Enhancers
  • 8.3. Hormonal Based Therapies

9. Anti-Obesity Therapeutics Market, by Route Of Administration

  • 9.1. Oral
    • 9.1.1. Capsules
    • 9.1.2. Tablets
  • 9.2. Injectable
    • 9.2.1. Intramuscular
    • 9.2.2. Subcutaneous
  • 9.3. Transdermal

10. Anti-Obesity Therapeutics Market, by Indication

  • 10.1. Obesity
  • 10.2. Overweight with Comorbidities
    • 10.2.1. Type 2 Diabetes
    • 10.2.2. Cardiovascular Diseases
    • 10.2.3. Hypertension
    • 10.2.4. Dyslipidemia
  • 10.3. Genetic Obesity Disorders
  • 10.4. Hypothalamic Obesity

11. Anti-Obesity Therapeutics Market, by End User

  • 11.1. Hospitals
  • 11.2. Specialty Clinics
  • 11.3. Weight Loss Centers
  • 11.4. Homecare Settings
  • 11.5. Ambulatory Surgical Centers

12. Anti-Obesity Therapeutics Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Anti-Obesity Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Anti-Obesity Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anti-Obesity Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Aardvark Therapeutics
  • 17.2. Altimmune, Inc.
  • 17.3. Amgen Inc.
  • 17.4. Antag Therapeutics ApS
  • 17.5. Ascletis Pharma Inc.
  • 17.6. AstraZeneca PLC
  • 17.7. Boehringer Ingelheim International GmbH
  • 17.8. Currax Pharmaceuticals LLC
  • 17.9. Eli Lilly and Company
  • 17.10. Hanmi Pharm. Co., Ltd.
  • 17.11. Innovent Biologics, Inc.
  • 17.12. Kailera Therapeutics
  • 17.13. Metsera, Inc.
  • 17.14. Novo Nordisk A/S
  • 17.15. Pfizer Inc.
  • 17.16. Rhythm Pharmaceuticals, Inc.
  • 17.17. Roche Holding AG
  • 17.18. Sciwind Biosciences
  • 17.19. Structure Therapeutics Inc.
  • 17.20. Sun Pharmaceutical Industries Ltd.
  • 17.21. Takeda Pharmaceutical Company Limited
  • 17.22. Teva Pharmaceutical Industries Ltd.
  • 17.23. Viking Therapeutics, Inc.
  • 17.24. Zealand Pharma A/S
  • 17.25. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GLP 1 RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLP 1 RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GLP 1 RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SEMAGLUTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SEMAGLUTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SEMAGLUTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIRAGLUTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIRAGLUTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIRAGLUTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TIRZEPATIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TIRZEPATIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TIRZEPATIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHENTERMINE TOPIRAMATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHENTERMINE TOPIRAMATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHENTERMINE TOPIRAMATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BUPROPION NALTREXONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BUPROPION NALTREXONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BUPROPION NALTREXONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SYMPATHOMIMETIC AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYMPATHOMIMETIC AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SYMPATHOMIMETIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CENTRALLY ACTING DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CENTRALLY ACTING DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CENTRALLY ACTING DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROTRANSMITTER MODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROTRANSMITTER MODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROTRANSMITTER MODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PERIPHERALLY ACTING DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PERIPHERALLY ACTING DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PERIPHERALLY ACTING DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FAT ABSORPTION BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FAT ABSORPTION BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FAT ABSORPTION BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL METABOLIC ENHANCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL METABOLIC ENHANCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL METABOLIC ENHANCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HORMONAL BASED THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HORMONAL BASED THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HORMONAL BASED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OBESITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OBESITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OBESITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OVERWEIGHT WITH COMORBIDITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OVERWEIGHT WITH COMORBIDITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OVERWEIGHT WITH COMORBIDITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DYSLIPIDEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DYSLIPIDEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DYSLIPIDEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENETIC OBESITY DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENETIC OBESITY DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENETIC OBESITY DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HYPOTHALAMIC OBESITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HYPOTHALAMIC OBESITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HYPOTHALAMIC OBESITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL WEIGHT LOSS CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL WEIGHT LOSS CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL WEIGHT LOSS CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 240. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 241. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 245. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 248. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 284. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 285. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 286. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 287. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 290. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 292. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 293. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 297. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 299. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 300. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 301. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 302. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 303. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 305. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 306. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 307. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 308. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 326. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 328. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2032 (USD MILLION)
  • TABLE 329. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GLP 1 RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 330. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 331. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 332. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CENTRALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 333. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, 2018-2032 (USD MILLION)
  • TABLE 334. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 336. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 337. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 338. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, 2018-2032 (USD MILLION)
  • TABLE 339. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 340. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 341. MEXICO ANTI-OBESITY THERAPEUTICS MARKET